This Chinese Startup Completes Series B Financing For Oncolytic Virus Development

This Chinese Startup Completes Series B Financing For Oncolytic Virus Development

Immvira Group Company announced this week the completion of series B financing for $58 million. The biotechnology startup focuses on the development of new generation oncolytic viruses as potential cancer therapeutics. Immvirva attracted a number of biotech investors. This round of financing was led by Huagai Capital, with participation by Apricot Capital, Cowin Capital. The funds … Read more

Verisim Life’s In Silico AI Aims To Replace Animal Testing To Improve Drug Development

Verisim Life’s In Silico AI Aims To Replace Animal Testing To Improve Drug Development

VeriSIM Life (VSL), a San Francisco-based biotechnology startup, builds artificial intelligence (AI)-enabled biosimulation models to accelerate drug development. The company’s BIOiSIM tool is an in-house technology that enables simulation and prediction of drug disposition in human and animal bodies. The company’s goal is lofty. VSL is attempting to model whole human biology to solve, in … Read more

This Startup Is Innovating In Real World Data And AI

This Startup Is Innovating In Real World Data And AI

Concerto HealthAI, a SymphonyAI Group portfolio company, is innovating in real world data (RWD) and AI solutions for precision oncology. The company’s mission is to bring together unique data assets, AI-based technologies, and top outcomes research and data science talent. Concerto HealthAI’s focus is on revolutionizing clinical and outcomes research to accelerate the insights benefiting … Read more

This Startup Is Innovating In Enzymatic DNA Synthesis

This Startup Is Innovating In Enzymatic DNA Synthesis

Ansa Biotechnologies, Inc, a Berkeley, CA-based startup, is developing a technique to control additions of a polymerase that use TdT for de novo DNA synthesis. The ability to synthesize “gene-length” DNA molecules (>500 bases) is invaluable for biological and biomedical research and is a key enabling technology for the rapidly growing field of synthetic biology. … Read more

This Startup Is Innovating In Protein Sythesizers

This Startup Is Innovating In Protein Sythesizers

Protein synthesizers speed up the production of enzymes, therapeutics and lab reagents. Toronto-based Liberumbio’s product use proprietary molecular and hardware technology, enabling biological manufacturer to bring speed, scalability and to reduce cost to protein synthesis. The market size of recombinant proteins today is $119 billion. But it’s expected to reach $400 billion just by 2025. … Read more

Meet IndieBio’s San Francisco Class 10 And New York Class 1

Meet IndieBio’s San Francisco Class 10 And New York Class 1

IndieBio announced its new batches of startups in June. The life sciences startup incubator allocates each team $250,000 in seed funding plus lab and co-working space and dedicated mentorship. Afterwards, each company becomes part of a network of IndieBio alumni, investors, and biotech entrepreneurs. This is New York’s first batch, and San Francisco’s tenth. Though … Read more